::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::

CODEN : IAJPBB
issn 2349-7750

News Updates Latest Volumes: COSMOS IMPACT FACTOR (2018)- 4.153, GLOBAL IMPACT FACTOR(2014) - 0.384, (2015) - 0.437, Indo American Journal of Pharmaceutical Sciences,

ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

RATE OF PREVALENCE OF HEPATOCELLULAR CARCINOMA IN PATIENTS OF HCV INFECTION AFTER DIRECT ANTIVIRAL TREATMENT

AUTHORS:

Dr Hafiza Saima Nawaz, Dr Hafiz Muhammad Adnan

ABSTRACT:

Objective: To determine the rate of prevalence of HCC (Hepatocellular Carcinoma) in the patients suffering from HCV infection after getting treatment with DAA (Direct Acting Antiviral). Methodology: This transverse research work was carried out in Sheikh Zayed Hospital Rahim Yar Khan from July 2018 to March 2020. We selected a sum of three hundred patients present with HCV genotype-3 with non-probability sampling method. All these patients were present with no past or current history of hepatocellular carcinoma. We gave the patients direct acting antiviral agents and followed these patients for complete six months after the completion of the treatment. Results were depending upon the quantitative PCR to evaluate the SVR (Sustained Virological Response) and ultrasound to examine the presence of any new abrasion. We presented the data in average, standard deviations, frequencies and percentages and we used the SPSS V.24 for the statistical analysis of collected information. Results: Among three hundred patients, 59.70% (n: 179) patients were males and 40.30% (n: 121) patients were from female gender. The mean age of the patients was 55.080 ± 5.6020 years. There were 71.30% (n: 214) patients, present with the compensated cirrhosis at onset of treatment and 28.70% (n: 86) patients were present with decompensated cirrhosis. There was achievement of sustained Virological response in 93.40% (n: 200) patients out of total 214 patients having compensated cirrhosis and 88.30% (n: 76) patients out of eighty-six were present with decompensated cirrhosis. After 6 months of treatment, 3.33% (n: 10) patients were present with the development of hepatocellular carcinoma, 0.70% (n: 2) patients in the compensated group and 2.70% (n: 8) patients present in decompensated group, out of these patients 6.60% (n: 5) patients achieved the sustained virological response. Conclusion: The rate of prevalence of hepatocellular carcinoma after the treatment through direct acting antiviral agents is much significant (3.30%) even after the achievement of sustained virological RESPONSE. There must be exercise of caution in prescribing the direct acting antiviral agents to the patients of HCV infection, keeping the abnormality of hepatocellular carcinoma in minds. KEYWORDS: Infection, Sustained Virological Response, Direct Acting Antiviral, Hepatocellular Carcinoma, Cirrhosis, Compensated, Decompensated, Onset, Prevalence.